Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Telomerase inhibition, oligonucleotides, and clinical trials

A Corrigendum to this article was published on 17 September 2002

This article has been updated

Abstract

Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2′-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Change history

References

  • Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF . 1997 J. Biol. Chem. 272: 11994–12000

  • Baker BF, Monia BP . 1999 Biochim. Biophys. Acta 1489: 3–18

  • Banerjee D . 2001 Curr. Opin. Investigat. New Drugs 2: 574–580

  • Bearss DJ, Hurley LH, Von Hoff DD . 2000 Oncogene 19: 6632–6641

  • Blasco MA, Lee H-W, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW . 1997 Cell 91: 25–34

  • Braasch DA, Corey DR . 2001 Chem. Biol. 8: 1–7

  • Counter CM, Hirte HW, Bachetti S, Harley CB . 1994 Proc. Natl. Acad. Sci. USA 91: 2011–2015

  • Crooke ST . 2000 Oncogene 19: 6551–6659

  • Elayadi A, Demieville A, Wancewicz EV, Monia BP, Corey DR . 2001 Nucl. Acids. Res. 29: 1683–1689

  • Feng J, Funk WD, Wang S-S, Weinrich SS, Avilion AA, Chiu C-P, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW, Villeponteau B . 1995 Science 269: 1236–1241

  • Freier SM, Altmann K-H . 1997 Nucl. Acids Res. 25: 4429–4443

  • Geary RS, Yu RZ, Levin AA . 2001 Curr. Opin. Investigat. New Drugs 2: 562–573

  • Grillone LR, Lanz R . 2001 Drugs Today 37: 245–255

  • Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JHM, Meyerson M, Weinberg RA . 1999 Nat. Med. 5: 2388–

  • Hamilton SE, Pitts AE, Katipally RR, Jia X, Davies BA, Rutter JP, Wright WR, Shay JW, Corey DR . 1997 Biochemistry 36: 11873–11880

  • Hamilton SE, Simmons CG, Kathriya I, Corey DR . 1999 Chem. Biol. 6: 343–351

  • Harley CB, Futcher AB, Greider CW . 1990 Nature 345: 458–460

  • Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC . 1990 Nature 346: 866–868

  • Harrington L, Zhou W, McPhail T, Oulton R, Yeung DSK, Mar V, Bass MB, Robinson MO . 1997 Genes Dev. 11: 3109–3115

  • Henry S, Steker K, Brooks D, Monteith D, Conklin B, Bennett CF . 2000 J. Pharmacol. Exper. Therapeu. 292: 468–479

  • Herbert B-S, Pitts AE, Baker SE, Hamilton SE, Wright WE, Shay JW, Corey DR . 1999 Proc. Natl. Acad. Sci. USA 96: 14726–14781

  • Herbert B-S, Wright AC, Passons CM, Wright WE, Iqbal Unnisa A, Kopelovich L, Shay JW . 2001 J. Natl. Cancer Inst. 93: 39–45

  • Khatsenko O, Morgan R, Truong L, York-Defalco C, Sasmor H, Conklin B, Geary RS . 2000 Antisense Nucl. Acid Drug Devel. 10: 35–44

  • Grillone LR, Lanz R . 2001 Drugs Today 37: 245–255

  • Geary RS . 2000 Antisense Nuc. Acid. Drug Dev. 10: 35–44

  • Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW . 1994 Science 266: 2011–2015

  • Lebedeva I, Stein CA . 2001 Ann. Rev. Pharm. Tox. 41: 403–419

  • Levin AA . 1999 Biochim. Biophys. Acta 1489: 69–84

  • Liu Y, Snow BE, Hande MP, Yeung D, Erdmann NJ, Wakeham A, Itie A, Siderovski DP, Lansdorp PM, Robinson MO, Harrington L . 2000 Curr. Biol. 10: 1459–1462

  • Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T . 2001 Cancer Res. 61: 3053–3061

  • Matthes E, Lehmann C . 1999 Nucl. Acids. Res. 27: 1152–1158

  • Marwick C . 1998 J. Am. Med. Assoc. 280: 871–

  • Meyerson M, Counter CM, Ng Eaton E, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA . 1997 Cell 90: 785–795

  • Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR . 1997 Science 277: 955–959

  • Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR . 1996 Nature Biotech. 14: 615–620

  • Pitts AE, Corey DR . 1998 Proc. Natl. Acad. Sci. USA 95: 11549–11554

  • Rusckowski M, Qu T, Chang F, Hnatowich DJ . 1997 Cancer (Supp.) 80: 2699–2705

  • Shammas MA, Simmons CG, Corey DR, Reis RJS . 1999 Oncogene 18: 6191–6200

  • Yuen A, Halsey J, Fisher G, Advani R, Moore M, Saleh M, Ritch P, Harker G, Ahmed F, Jones M, Polikoff J, Keiser W, Kwoh TJ, Holmund J, Dorr A, Sikic B . 2001 American Society of Clinical Oncology abstract 1234

  • Zhang X, Mar V, Zhou W, Harrington L, Robinson MO . 1999 Genes Dev. 13: 2388–2399

Download references

Acknowledgements

This work was supported by grants from the National Institutes of Health (CA 85363, GM 60642) and the Robert A Welch Foundation (I-1244)

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David R Corey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corey, D. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 21, 631–637 (2002). https://doi.org/10.1038/sj.onc.1205063

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205063

Keywords

This article is cited by

Search

Quick links